Glioblastoma Clinical Trials in Philadelphia, Pennsylvania

17 recruitingPhiladelphia, Pennsylvania

Showing 117 of 17 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Phase 2Phase 3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled7 locationsNCT04732065
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled20 locationsNCT06894979
Recruiting
Phase 1

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Glioblastoma
University of Pennsylvania9 enrolled1 locationNCT06973096
Recruiting
Phase 1

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Recurrent Glioblastoma
University of Pennsylvania12 enrolled1 locationNCT07209241
Recruiting
Phase 3

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Glioblastoma
NovoCure GmbH741 enrolled93 locationsNCT06556563
Recruiting
Phase 2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683
Recruiting
Phase 3

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Brain TumorGlioblastomaGBM+1 more
Ivy Brain Tumor Center450 enrolled95 locationsNCT06388733
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Not Applicable

WBSI Guided Personalized Delivery of TTFields

GBMTumor, BrainGlioma Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine155 enrolled2 locationsNCT05086497
Recruiting
Early Phase 1

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

GlioblastomaRecurrent GlioblastomaGlioblastoma Multiforme of Brain
Abramson Cancer Center at Penn Medicine15 enrolled2 locationsNCT06613841
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

GlioblastomaMalignant GliomaRecurrent Glioblastoma+3 more
Sabine Mueller, MD, PhD20 enrolled20 locationsNCT04323046
Recruiting
Phase 2

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Glioblastoma
Philogen S.p.A.90 enrolled8 locationsNCT06336291